Approval date (August/2022) by HPRA
You can alternatively download this material from this link
This site is intended for healthcare professionals registered within the Republic of Ireland. If you are a member of the public, please click here.
Approval date (August/2022) by HPRA
You can alternatively download this material from this link
Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.